Why We Invested in Ailin?

In a world increasingly focused on personal health and well-being, the importance of accessible and accurate medical diagnostics cannot be overstated. This is where Ailin, one of Decelera 2023 Alumni, enters the picture, promising to revolutionize home-based medical diagnostics. We at Decelera are delighted to announce our investment in Ailin, and in this blog we explain you why.

Innovative Home-Based Diagnostic Solution

Ailin stands out with its one-liner promise: Home-based medical diagnostic solutions for simplified access and enhanced accuracy at a reduced cost. The service is especially beneficial for patients with limited mobility or those seeking private diagnoses, delivering results within 48 hours.

Addressing a Substantial Market

The prevention and personalized medicine market is not just vast but also rapidly growing. With a current size of $5 billion in Spain and a staggering $81 billion in Europe, coupled with an exponential growth rate of 10% CAGR, Ailin is tapping into a significant and expanding market.

Clear Competitive Edge

What sets Ailin apart from its competitors is its quicker delivery times and more affordable pricing. Additionally, the CE marking enhances its credibility and market standing, further solidifying its competitive advantage.

Robust Defensibility

Ailin’s CE mark not only provides a quality assurance but also places it approximately 18 months ahead of its Spanish competitors. Furthermore, Ailin’s agreement with Clinica de Navarra ensures the capacity to support the company’s potential growth across Spain.

Exceptional Founder and scientific-driven Team

The driving force behind Ailin is its solo founder, Isabel, who showcased her remarkable ambition and passion during Decelera 2023. These traits are often the hallmarks of successful founders, and Isabel’s dedication and vision for Ailin stood out remarkably. But she is not alone, she has a scientific-driven team that knows the health industry, both B2C and B2B2C in a scientific perspective which allows them to meet the sales and growth objectives.

In conclusion, our investment in Ailin aligns with our ethos of supporting innovative solutions that address critical global challenges. Ailin’s approach to home-based medical diagnostics not only aligns with the evolving landscape of healthcare but also offers a practical solution for personalized and preventative medicine. We are excited to be part of Ailin’s journey and look forward to its continued growth and impact in transforming healthcare access and accuracy.

Our belief in Ailin’s vision is a testament to our commitment to investing in companies that are not just business-savvy but also socially responsible, paving the way for a healthier, more accessible future.